Cookie Policy - To find out more about cookies on this website, see our privacy policy

Cookie Policy

We Help Companies Find New Sales Opportunities

We Help Companies Find New Sales Opportunities

Chemicals & Pharmaceuticals - 2006






















Ark Therapeutics is to raise £6.1m in a share placing to fund the development of its early-stage pharmaceuticals.

Fibres Worldwide, the Grimsby-based fibres manufacturer with 170 staff, is to be bought out of administration by China National Bluestar Corporation.

Cognetas is planning to sell Azelis, the Italian chemicals distributor that owns Runcorn-based Chance & Hunt, to 3i for £212m.

RPM International of the US has acquired The Dane Group, the Manchester-based pigments manufacturer, for £11m.

GlaxoSmithKline is to acquire Domantis, the Cambridge-based biotechnology research company, for £230m.

Inpharmatica, the drug discovery company with 30 staff in Cambridge and London, is to be acquired by the BioFocus division of Galapagos for £8.4m.

Equazen Nutraceuticals, the London-based supplements supplier, has been acquired by Galencia of Switzerland for undisclosed terms.

Croda has won approval to build a two-storey extension to the laboratory at its dietary supplements and veterinary products factory in Leek.

Ecolab is to set up a call centre for its pest elimination division in Caerphilly, with the creation of 55 jobs.

Intertek has acquired Alta Analytical Laboratory Corporation, the US pharmaceutical testing company, for £13m.

Servier of France is considering plans to set up a pharmaceuticals research centre near Slough, with the creation of hundreds of jobs.

Biofusion has raised £7.7m in a share placing, and has also announced a deal with Cardiff University to commercialise research-generated IP and to expand into non-life science research.

The Specials Laboratory is planning to expand the workforce at its Northumberland-based pharmaceuticals business from 120 to 145 and set up an extra 7,000 sq ft of office space.

Unilever is to expand its deodorants research and development centre at Seacroft in Leeds in 2007, with the creation of 28 jobs.

Schering Health Care is to close its Burgess Hill headquarters in July 2007 with the loss of up to 130 jobs, in order to relocate to parent company Bayer's site in Newbury.

Genetix Group has acquired Applied Imaging Corporation, the cell imaging company with 65 staff in Newcastle and the US, for £14m.

ICI is to sell Quest, the Dutch flavours and fragrances business with 3,400 staff at sites including Ashford and Bromborough, to Givaudan of Switzerland for £1.2bn.

Minster Pharmaceuticals is to raise £0.6m in a share placing to fund the expansion of its Essex-based drug development business.

Vectura is to acquire Innovata, the Nottingham-based supplier of inhaler products for asthma and diabetes, for £129m.

Himar Performance Specialties, the Bradford-based industrial chemicals company, is to be acquired by Willington for up to £1m.

GlaxoSmithKline has announced plans to invest £60m in the expansion of its pharmaceuticals factory in Montrose over the next three years, with the creation of up to 150 jobs.

AstraZeneca is planning to double the size of its recently-acquired Cambridge Antibody Technology subsidiary by extending its research into new disease areas, with the creation of 200 jobs.

Archimedes Pharma has acquired Link Pharmaceuticals of Horsham, West Sussex, for almost £25m.

Kiotech International is to acquire Agil, the Reading-based supplier of animal feed additives with 11 staff, from Lawrence for £5.5m.

Excelsyn Engineering Technology, the Newcastle-based developer of manufacturing and research facilities for the pharmaceutical industry, is planning to create 30 new jobs over the next two years.

Byotrol is planning to raise £4.6m in a share placing to fund the expansion of its Manchester-based biocides business.

Katoen Natie of Belgium is to set up a chemicals storage and distribution centre near the Millennium Chemicals plant on Hobson Way in North East Lincolnshire, with the creation of scores of new jobs.

BioProgress is to acquire the US pharmaceutical trading assets of AirPharma for £4.2m, including 20 brands.

Concateno has acquired Medscreen, the London-based provider of drug and alcohol testing services with 49 staff in Canary Wharf, 60 UK collection officers and 260 overseas contractors, for £30m.

Vascutek, the manufacturer of fabric grafts for arteries, is planning a £5m expansion at its factory in Renfrewshire with the creation of 212 jobs over the next five years.

Banner Chemicals is looking to relocate its chemicals storage and distribution depot and up to 25 staff from East London to make way for the 2012 Olympics, and is considering sites in Middlesbrough and Liverpool.

Synexus Clinical Research is to acquire Clinical Research Centers of South Africa for up to £1.8m, as part of a strategy to create a multi-country clinical trials operation.

Thomson Scientific is in negotiations to set up a 52,000 sq ft headquarters at the Johnson Building in London's Hatton Garden.

Terra Industries, the fertiliser manufacturer with 400 staff at sites in Billingham and Bristol, has announced plans to merge with Kemira GrowHow, the Finnish company that also has about 400 UK staff.

Minova, the Chipping Norton-based speciality chemicals company with 17 sites in ten countries, is to be acquired by Orica of Australia for £357m.

Aesica is to acquire a pharmaceuticals factory at Ponders End in north London from Merck & Co for undisclosed terms, with the transfer of 74 staff and the creation of 20 new jobs over the next few months.

NPIL Pharma of Huddersfield has secured a £0.5m investment from Yorkshire Forward to fund the development of a new pharmaceutical process technology called SCRAM.

Cancer Research UK and the government are to provide £35m of funding for the development of 17 new experimental drug centres across the country, in order to transform scientific discoveries into effective treatments.

Pfizer is to acquire PowderMed, the Oxford-based DNA vaccines company, for up to £214m.

GlaxoSmithKline is to acquire CNS, the US supplier of consumer healthcare products, for £303m.

Acambis has sold Berna Products, the US-based distributor of oral typhoid vaccines with 15 staff, to Crucell for £9m.

West Pharmaceutical Services is to create ten new jobs in Bodmin over the next 18 months, as part of a project to double the size of its tooling facility for closure systems and syringe components.

Johnson Matthey is seeking permission to expand its chemicals factory in Royston, with the creation of more than 50 jobs.

Huntsman is to sell its Teesside-based European base chemicals and polymers division to Saudi Basic Industries Corporation by the end of the year, with the transfer of about 840 jobs.

Sinclair Pharma is to acquire Ashbourne Pharmaceuticals, the Northampton-based pharmaceuticals marketing company, for £1.3m.

Ortho-Clinical Diagnostics has started work on the development of a new medical diagnostic tests factory at Pencoed, near Bridgend, which will replace its existing plant in Cardiff by 2010.

Ardana has raised £11m in a share placing to fund the expansion of its Edinburgh-based pharmaceuticals business.

Fujifilm is investing £2.5m in the expansion of its imaging colourants research and development centre in Grangemouth.

Biocare Solutions is to raise £6.5m in a flotation on Aim later this month, to fund the expansion of its natural cleaning products business.

Eastman Chemical has announced plans to expand production of acetate tow at its factory in Workington over the next two years, with the creation of more than 100 jobs.

Vindon Healthcare is planning to relocate to larger premises to meet rising demand for its pharmaceutical testing facilities.

The Scottish Executive is to invest £10m at genetic medicine centres in Glasgow, Edinburgh, Aberdeen and Dundee over the next two years, including the training of staff and new equipment.

Astex Therapeutics is looking to raise up to £25m of venture capital to fund the expansion of its Cambridge-based drug discovery business.

Acetate Products, the acetate manufacturer with 750 staff in Derby and Coventry, is to be acquired by Celanese Corporation of the US for undisclosed terms.

Calderdale & Huddersfield NHS Foundation Trust is to build a new £8m pharmaceutical manufacturing unit at Acre Mills, Lindley, and work is due to start in the autumn.

Dermasalve Sciences has acquired Healthy & Essential, the Fleetwood-based distributor of skin care products, for about £1m.

Provalis is to sell its medical diagnostics business to Bio-Metrics UK for £1.6m, and the remaining company will be placed into members' voluntary liquidation.

Rosemont Pharmaceuticals, the Leeds-based supplier of liquid medicines with 170 staff, has undergone a £93m management buy-out from US-based Savient Pharmaceuticals.

Lipoxen has raised £2.6m from the Serum Institute of India to fund the expansion of its London-based biopharmaceuticals business.

PZ Cussons is to set up a new £15m shower gels factory in Manchester by 2008, and workers will transfer from its existing site.

Cozart has acquired HL Scandinavia, the Swedish drugs testing company, for about £1m.

Wellcome Trust is to invest £10m in the development of a stem cell research centre at the University of Cambridge.

Paradigm Therapeutics has raised about £7m of private equity from existing investors to fund the expansion of its Cambridge-based drug discovery business.

BBI Holdings is to acquire Qnostics, the Glasgow-based supplier of molecular quality control reagents, for an initial £0.2m.

Inspicio is to acquire Eclipse Scientific, the Cambridgeshire-based provider of chemical and microbiological testing services, from Clearbrook Capital Partners for £47m.

Premier Research Group has acquired Scirex Corporation, the US-based provider of outsourced clinical services to the biotechnology and pharmaceutical industries with offices in London and Poland, for £16m.

Shield Medicare, the supplier of consumables to the pharmaceutical industry and the NHS, is to build a £5m facility at the Baglan Energy Park in Port Talbot, with the creation of 120 jobs.

Curidium Medica has raised £1.5m in a share placing to fund the expansion of its drug discovery business.

Penn Pharmaceutical Services is to invest £1m in the expansion of its Tredegar-based pharmaceutical outsourcing business, including new clean rooms, laboratory facilities and the creation of 30 jobs over the next two years.

United Drug has acquired MASTA, the Leeds-based medical advisory service and vaccines distributor with 60 staff, for £15m.

BBI Holdings has acquired Audiometrics and CDx, the Sunderland-based suppliers of blood glucose meters, for an initial £0.2m.

Wellcome Trust has announced plans to invest £84m in the development of clinical research facilities at 11 universities, as part of the UK Clinical Research Collaboration consortium.

Wyeth Pharmaceuticals is seeking a suitable site to open a 100,000 sq ft office between Reading and Slough.

ICI is to sell Uniqema, the oleochemicals and surfactants manufacturer with sites in Bromborough, Wilton, continental Europe, Asia and the US, to Croda International for £410m.

J Pickles Healthcare has undergone a management buy-out for undisclosed terms, securing the future of more than 25 jobs at its health and beauty products business in Lancashire.

European Colour, the Stockport-based pigments supplier, is to be acquired by a newly-formed company called Pochteca for £2.6m.

Exwold Technology, the Hartlepool-based agrochemicals company with 65 staff, has undergone a management buy-out, and has also announced the acquisition of Woking-based Crack Processing.

BioProgress is to acquire Segix Farma, the Italian pharmaceuticals company that specialises in the anti-infective, gastrointestinal and oncology sectors, for up to £1.3m.

ClinPhone has raised £56m in a flotation, in order to reduce debt and fund the expansion of its Nottingham-based clinical trials technology business.

Celsis International is to acquire In Vitro Technologies, the US provider of testing products and services to the pharmaceutical industry, for £16m.

Intercell is to expand its vaccines facility in Livingston, in order to create a 30,000 sq ft multi-purpose manufacturing unit with 15 new jobs.

Curidium, the London-based drug discovery company, is to be acquired by Aim-listed Cielo Holdings in a £3.9m reverse takeover.

CPS, the manufacturer of chemicals for the printing industry, is to open a new factory at the Wantage site of sister company MacDermid Autotype in July, with the creation of 20 jobs.

Synexus Clinical Research is to combine its Wigan and Chorley operations onto one site in Bolton, and has also announced the £1m acquisition of Diagnostic Units, the Hungarian clinical trials company.

Yule Catto has sold its Reabrook chemical products business in Derbyshire to a management buy-out for £4m, securing the future of 200 jobs.

Linde has been told to sell its UK gas operations, in order to win EC approval for its proposed £8bn acquisition of BOC.

Johnson Matthey is looking to spend up to £200m on acquisitions to expand its speciality chemicals business.

AstraZeneca is planning to set up a £53m pharmaceuticals research centre in China by 2009.

Tristel is to acquire Vernagene, the Bolton-based supplier of water treatment and hygiene control products, for £1m.

Personal Screening has acquired Mermaid Diagnostics, the spin-out from the University of Birmingham that has developed a nicotine testing device.

Albion Chemicals is to relocate its Glasgow-based chemicals business and 50 jobs to a new £8m site at Clydesmill, Cambuslang.

Alliance Pharma is to acquire Caraderm, the Northern Ireland-based developer of dermatological sprays, for £0.3m.

Fulcrum Pharma is setting up a new drug development office at the Heriot-Watt University Research Park in Edinburgh, with the creation of up to 12 jobs.

Asterion has raised £0.4m of venture capital to fund the expansion of its Sheffield-based drug development business.

Vectura and Unilever Ventures are forming a joint venture to develop prescription products through a newly-created company called PharmaKodex.

Tarmac Minerals & Materials, the Stoke-on-Trent-based company with 70 staff, has been acquired by Prince Minerals of the US for about £4m.

AstraZeneca is to acquire Cambridge Antibody Technology, the Cambridge-based biotechnology company with 300 staff, for £700m.

GlaxoSmithKline is to create 100 new jobs at its pharmaceuticals plant in Montrose over the next few months, in order to expand production of rosiglitazone and carvedilol.

Alliance Pharma has raised £2.5m in a share placing to fund the development of its Chippenham-based pharmaceuticals business.

United Drug has acquired Endoscopy UK, the Forest of Dean-based medical products distributor, for £6.1m.

Invitrogen Corporation, the multinational life sciences company, is to set up a £17m European headquarters at Inchinnan in Renfrewshire, securing 555 jobs and creating an additional 45.

The Biotechnology & Biological Sciences Research Council (BBSRC) is investing £27m in three new centres for integrative systems biology at the universities of Edinburgh, Nottingham and Oxford.

The University of Wales in Bangor is investing £10m in the appointment of 50 additional teaching staff over the next four years, including the expansion of its chemistry, environmental systems and marine biology departments.

Alchemy Laboratories, the Dundee-based manufacturer of diagnostic tests, is to be acquired by BBI for £4.5m.

Medisys, the supplier of blood glucose testing kits, is to sell its operating business to Arkray of Japan for £24m, and will now focus on investments in biopharmaceutical and diagnostic companies.

Allergy Therapeutics has raised £18m in a share placing to fund the development of vaccines for a number of allergies.

Medical House is to create 75 new jobs in Sheffield over the next four years, having secured a £0.8m grant to expand the premises of its orthopaedics and drug delivery operations.

Sciantec Analytical Services, the Thirsk-based chemical analysis laboratory with 19 staff, has merged with NRM of Bracknell to form holding company Cawood Scientific.

Protherics, the biotechnology company developing a new treatment for sepsis, is to invest £10m in research this year.

ICI is to sell Cimsec, the manufacturer of tile adhesives and grouts with annual sales of £14m, to Henkel of Germany for undisclosed terms.

GlaxoSmithKline is to invest £25m at its pharmaceuticals plant in Montrose, securing the future of 250 jobs, having dropped plans to close the site.

McBride has acquired the household liquids business of Sanmex International for £6.5m.

Bioganix of Leominster is planning to raise £2m in a flotation on Aim, in order to fund the development of organic waste processing factories across the country.

Wyeth and Scottish Enterprise are to invest £50m in medical research work in Scotland, including drug development at the universities of Glasgow, Aberdeen, Edinburgh and Dundee, and a central research centre with 50 staff in Dundee.

Stem Cell Sciences, the Edinburgh-based biotechnology company, is planning to set up an automated cell-production facility in Cambridge and a sales office in California.

Chroma Therapeutics has raised £30m from Nomura Phase 4 Ventures and other investors to fund the development of cancer drugs based on chromatin biology.

Ineos Compounds is considering plans to relocate its chemicals business and up to 63 jobs from Helsby to the main Ineos site at Runcorn.

ICI has acquired the fragrance business of US-based Shaw Mudge for undisclosed terms.

Zanza Healthcare has secured a £0.8m finance package from the Merseyside Special Investment Fund's Mezzanine Fund and through invoice discounting from Bibbys to fund the development of its non-prescription pharmaceuticals range.

Cytomyx Holdings is to sell its Cytomyx Limited subsidiary to Serologicals UK for £4m, in order to focus on its US-based biorepository business.

Brecon Pharmaceuticals, the pharmaceutical services company with 280 staff, has been acquired by AmerisourceBergen of the US for £28m.

Sinclair Pharmaceuticals is to acquire Group CS Dermatologie, the French skincare company, for £37m.

Biotrace International has acquired the remaining 61% stake in Target Diagnostica, the Italian supplier of microbiology products, for about £0.3m.

BOC, the industrial gases group, is to be acquired by Linde of Germany for £8bn.

Renovo is reviving plans to raise up to £40m in a flotation to fund the development of its Manchester-based biotechnology business.

Tepnel Life Sciences has acquired the Cambridge-based GenXTrak DNA extraction business from Whatman for undisclosed terms.

TDG has acquired Mond, the Belgian speciality chemicals distributor, for £18m, and is now seeking further acquisitions.

Tepnel Life Sciences is to set up a new pharmaceuticals outsourcing centre in Livingston, including a laboratory, office and storage space, with the creation of 20 jobs.

Syntopix is planning to raise £6m in a flotation on Aim to fund the expansion of its drug development business.

Skyepharma is planning to relocate its London headquarters from Piccadilly to a less expensive area, in order to cut costs.

GlaxoSmithKline is to acquire the Pliva Research Institute, which has 130 staff, from Pliva of Croatia for up to £29m.

Fulcrum Pharma is to acquire Quadramed, the West Sussex-based clinical trials regulatory consultancy, for up to £1.6m.

Biotrace International has sold Ruskinn, its Bridgend-based life sciences business with eight staff, to management for about £1m.

The University of Hertfordshire is planning to build a bioscience research and development centre in Welwyn Garden City, having secured a £8m grant from the East of England Development Agency.

Harriman Chemsult, the London-based chemical industry consultancy, has been acquired by Access Intelligence for undisclosed terms.

Johnson Matthey is to acquire Davy Process Technology, the developer of chemical process technologies with 175 staff at sites in London and Stockton-on-Tees, from Yukos International for £40m.

Provalis is to sell most of its Provalis Healthcare division to the Kogen affiliate of Galen for about £10m, in order to focus on medical diagnostics.

Synexus Clinical Research has acquired Skandynawskie Centrum Medyczne, the Polish pharmaceutical clinical trials company, for up to £2.3m.

Amgen of the US is planning to expand its UK-based biotechnology operations over the next ten years, with a £100m investment at sites in Uxbridge and Cambridge.

Eisai of Japan is planning to set up a £75m UK headquarters in Hatfield by 2008, with the creation of 500 jobs in pharmaceuticals research, clinical development and production.

Rentokil Initial is to acquire JC Ehrlich, the US pest control company with 42 outlets in seven states, for £80m.

Euroderm Research is to open a £4m clinical trial centre in Manchester over the next two years, and a second £2m site is also planned at Edinburgh Royal Infirmary.

Cookson has sold its SCS speciality coatings business to Bunker Hill Capital for £32m.